Mirae Asset Global Investments Co. Ltd. Sells 42,869 Shares of Natera, Inc. (NASDAQ:NTRA)

Mirae Asset Global Investments Co. Ltd. lowered its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 45.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,701 shares of the medical research company's stock after selling 42,869 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Natera were worth $8,198,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in NTRA. Yousif Capital Management LLC bought a new stake in Natera in the fourth quarter valued at approximately $207,000. GDS Wealth Management boosted its holdings in Natera by 245.0% in the fourth quarter. GDS Wealth Management now owns 12,463 shares of the medical research company's stock valued at $1,973,000 after acquiring an additional 8,851 shares during the last quarter. Hodges Capital Management Inc. bought a new stake in Natera in the fourth quarter valued at approximately $372,000. SYM FINANCIAL Corp bought a new position in shares of Natera during the 4th quarter worth approximately $256,000. Finally, SeaBridge Investment Advisors LLC bought a new position in shares of Natera during the 4th quarter worth approximately $2,894,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 4,858 shares of the business's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22. Following the completion of the transaction, the insider now owns 114,912 shares of the company's stock, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Fesko sold 663 shares of the business's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at $27,739,941.88. The trade was a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 312,394 shares of company stock valued at $52,333,520 in the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Natera Stock Performance

NTRA traded down $2.48 during trading hours on Tuesday, hitting $169.71. The stock had a trading volume of 1,553,272 shares, compared to its average volume of 1,345,451. The company's fifty day simple moving average is $167.72 and its 200 day simple moving average is $141.94. Natera, Inc. has a 1 year low of $67.33 and a 1 year high of $183.00. The stock has a market cap of $22.41 billion, a PE ratio of -96.43 and a beta of 1.66. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same quarter last year, the firm posted ($0.95) EPS. The firm's revenue for the quarter was up 63.9% on a year-over-year basis. Equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Robert W. Baird increased their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. TD Cowen increased their price target on Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Leerink Partners increased their target price on Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Piper Sandler lifted their price target on shares of Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. Finally, StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and an average price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.